<DOC>
	<DOC>NCT02796872</DOC>
	<brief_summary>This survey is a multicenter, double-blind, randomized, controlled, parallel-designed, prospective trial and is intended to evaluate the Bimuno GOS effects on growth, tolerance, gut health, fecal flora and immune function.</brief_summary>
	<brief_title>The Effect of Feeding Infant Formula With Bimuno Galactooligosaccharide (GOS)</brief_title>
	<detailed_description />
	<criteria>o 15 ± 3 days of age at randomization, inclusive (day of birth is considered day 0) Singleton birth Gestational age of 3742 weeks (36 weeks and six days is considered 36 weeks gestational age) Birth weight of 2500g to 4000g Signed informed consent obtained for infant's participation in the survey Parent or guardian of infant agrees not to enroll infant in another interventional clinical research survey while participating in this survey APGAR score after 5 minutes of life &gt; 7 Consuming only one source of nutrition Formulafed infant: Infant consuming infant formula as the sole source of nutrition for 7 consecutive days prior to randomization Breastfed infant: Infant consuming mother's breast milk as the sole source of nutrition for 7 consecutive days prior to registration Infant with inborn malformation and with hereditary and/or chronic and/or inborn diseases requiring hospital care superior to 7 days Diseases jeopardizing intrauterine growth Weight at Visit 1 is &lt;95% of birth weight [(weight at Visit 1÷birth weight) x 100 &lt;95%] Infant born from mother suffering from metabolic and/or chronic diseases Infant with an acute infection or gastroenteritis at time of randomization or registration Infant consuming supplemental foods Evidence of feeding difficulties or formula intolerance, such as vomiting or poor intake at time of randomization or registration Infant is immunocompromised (according to a doctor's diagnosis of immunodeficiency such as Combined Immunodeficiencies, DiGeorge Syndrome, WiskottAldrich Syndrome, Severe Congenital Neutropenia and Secondary Immunodeficiencies linked to HIV infection, Down Syndrome or others) and children with known head/brain disease/injury such as Microcephaly, Macrocephaly or others</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Days</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>